Stockscreener 앱 받기
7.855
2.42%
-0.195
전일 마감가:
$8.05
열려 있는:
$8.04
하루 거래량:
26,375
Relative Volume:
0.36
시가총액:
$756.70M
수익:
$106.66M
순이익/손실:
$15.16M
주가수익비율:
84.01
EPS:
0.0935
순현금흐름:
$6.37M
1주 성능:
+2.28%
1개월 성능:
+9.40%
6개월 성능:
+3.76%
1년 성능:
-25.90%
1일 변동 폭
$7.72
$8.04
1주일 범위
$7.5297
$8.377
52주 변동 폭
$6.11
$13.75
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(858) 567-7770
주소
12770 HIGH BLUFF DRIVE, SAN DIEGO
GYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.855 | 775.48M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.38 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | Jefferies | Buy |
| 2025-08-26 | 개시 | H.C. Wainwright | Buy |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
US Stocks Recap: Can Gyre Therapeutics Inc expand into new marketsWeekly Trade Analysis & Community Driven Trade Alerts - baoquankhu1.vn
Portfolio Recap: Is BCGWW a good ESG investment2025 Market Overview & Community Verified Swing Trade Signals - baoquankhu1.vn
Quarterly Risk: Does Evolus Inc have high return on assetsJuly 2025 WrapUp & High Accuracy Swing Trade Signals - baoquankhu1.vn
Tech Rally: Is TRTNPRC stock a value trapWeekly Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Pulse: Will Gyre Therapeutics Inc outperform tech stocksJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Ideas Watch: What are analysts price targets for Gyre Therapeutics IncIPO Watch & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Gains Report: How Gyre Therapeutics Inc stock valuations compare to rivalsJuly 2025 Sentiment & Weekly Stock Breakout Alerts - Bộ Nội Vụ
How Gyre Therapeutics Inc. stock compares to growth peersTrade Risk Assessment & Safe Entry Point Alerts - Улправда
Aug Big Picture: Will Gyre Therapeutics Inc stock benefit from commodity pricesJuly 2025 Closing Moves & Reliable Intraday Trade Alerts - Bộ Nội Vụ
Will Dynagas LNG Partners LP stock deliver consistent dividends2025 Breakouts & Breakdowns & Verified Short-Term Plans - Улправда
What margin trends mean for Mach Natural Resources LP stockSwing Trade & Capital Efficiency Focused Ideas - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7%Time to Sell? - MarketBeat
Gyre Therapeutics, Inc. Announces Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 - marketscreener.com
GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpShould You Buy? - MarketBeat
Gyre Therapeutics stock soars after positive pre-NDA meeting in China - Investing.com Nigeria
Gyre Therapeutics stock soars after positive pre-NDA meeting in China By Investing.com - Investing.com South Africa
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Gyre Pharmaceuticals advances liver fibrosis drug toward China approval By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Pre-NDA Meeting Success for Hydronidone - TradingView — Track All Markets
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - manilatimes.net
Experimental liver fibrosis drug in China moves closer to patient use - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of "Hold" by Analysts - MarketBeat
Info Edge (India) Limited Stock Approaches Key Moving AverageLong-Term Growth Stocks & High Profit Market Ideas - bollywoodhelpline.com
Gyre Therapeutics president sells $45,380 in stock - MSN
Industries Limited (511034) Hits 52 Week HighSwing Trading Ideas & Build Diversified Portfolios With Ease - bollywoodhelpline.com
Undiscovered Gems in the US Market to Explore This December 2025 - Yahoo Finance
Published on: 2025-12-21 18:19:37 - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6% – Time to Sell? - Defense World
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Will Gyre Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Breakouts & Low Drawdown Investment Strategies - Улправда
Gyre Therapeutics Earnings Notes - Trefis
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6%Time to Sell? - MarketBeat
Why Gyre Therapeutics Inc. stock remains on buy lists2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда
Levels Update: Is Gyre Therapeutics Inc. stock vulnerable to regulatory risks2025 Major Catalysts & Weekly Momentum Picks - Улправда
Will Gyre Therapeutics Inc. stock deliver consistent dividends2025 Market WrapUp & Reliable Price Action Trade Plans - Улправда
Does Gyre Therapeutics Inc. stock trade at a discount to peers2025 Geopolitical Influence & AI Driven Price Forecasts - Улправда
Gyre therapeutics president Ma Songjiang sells $45,434 in stock - MSN
US High Growth Tech Stocks to Watch - Yahoo Finance
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 5.9%Should You Sell? - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
GNI Group’s Subsidiary Completes Enrollment for Key Clinical Trial - MSN
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.3%Time to Buy? - MarketBeat
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Gyre Therapeutics Stock Built to Withstand a Pullback? - Trefis
Regarding video postings related to our company group information on some social networking services (SNS). - 富途牛牛
Published on: 2025-11-27 08:38:09 - moha.gov.vn
Is Gyre Therapeutics Inc a good long term investmentMarket Depth Overview & Free Unmatched Market Performance - earlytimes.in
Is Gyre Therapeutics Inc. stock a dividend growth opportunity2025 Short Interest & Real-Time Volume Triggers - newser.com
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):